Search Results - "Taniwaki, Masaya"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Activation of KIF4A as a Prognostic Biomarker and Therapeutic Target for Lung Cancer by TANIWAKI, Masaya, TAKANO, Atsushi, ISHIKAWA, Nobuhisa, YASUI, Wataru, INAI, Kouki, NISHIMURA, Hitoshi, TSUCHIYA, Eiju, KOHNO, Nobuoki, NAKAMURA, Yusuke, DAIGO, Yataro

    Published in Clinical cancer research (15-11-2007)
    “…Purpose and Experimental Design: To identify molecules that might be useful as diagnostic/prognostic biomarkers and as targets for the development of new…”
    Get full text
    Journal Article
  5. 5

    Organizing pneumonia in a carrier of human T-cell lymphotropic virus type-1 by Yamasaki, Masahiro, Taniwaki, Masaya, Funaishi, Kunihiko, Hattori, Noboru

    Published in Annals of thoracic medicine (01-01-2020)
    “…Human T-cell lymphotropic virus type-1 (HTLV-1)-associated bronchioloalveolar disorders (HABAs) are pulmonary disorders with various interstitial lung disease…”
    Get full text
    Journal Article
  6. 6

    A Rare Combination of Dermatomyositis, Interstitial Pneumonia, and Lung Cancer in a Patient Treated with Immunosuppressive Therapy and Chemotherapy by Daido, Wakako, Yamasaki, Masahiro, Morio, Yuka, Funaishi, Kunihiko, Ishiyama, Sayaka, Deguchi, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki, Hattori, Noboru

    Published in Internal Medicine (01-01-2018)
    “…We herein report the rare case of co-occurring dermatomyositis (DM), interstitial pneumonia (IP), and lung cancer in a 59-year-old man. Computed tomography…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Pericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two Cases by Yamasaki, Masahiro, Daido, Wakako, Saito, Naomi, Funaishi, Kunihiko, Okada, Takenori, Kawamoto, Kazuma, Matsumoto, Yu, Matsumoto, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki, Hattori, Noboru

    Published in Frontiers in oncology (22-01-2019)
    “…Nivolumab is an immune checkpoint inhibitor (ICI) that has shown efficacy for treating non-small cell lung cancer and has become a standard therapy for…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report by Nabeshima, Shinji, Yamasaki, Masahiro, Matsumoto, Naoko, Takaki, Shintaro, Nishi, Yumi, Kawamoto, Kazuma, Taniwaki, Masaya, Ohashi, Nobuyuki, Hattori, Noboru

    “…•Several immune-related adverse events including liver injury have been reported to be associated with immune checkpoint inhibitor (ICI) therapy; however,…”
    Get full text
    Journal Article
  11. 11

    Multiple patchy pulmonary consolidation in granulomatosis with polyangiitis by Yamasaki, Masahiro, Taniwaki, Masaya, Nakano, Shota, Matsumoto, Naoko, Nabeshima, Shinji, Hattori, Noboru

    Published in Respirology case reports (01-10-2020)
    “…Key message Multiple patchy pulmonary consolidations that are unresponsive to antibiotics and/or exist at peri‐bronchial sites and bloody bronchoalveolar…”
    Get full text
    Journal Article
  12. 12

    Characterization of SEZ6L2 cell‐surface protein as a novel prognostic marker for lung cancer by Ishikawa, Nobuhisa, Daigo, Yataro, Takano, Atsushi, Taniwaki, Masaya, Kato, Tatsuya, Tanaka, Sonosuke, Yasui, Wataru, Takeshima, Yukio, Inai, Kouki, Nishimura, Hitoshi, Tsuchiya, Eiju, Kohno, Nobuoki, Nakamura, Yusuke

    Published in Cancer science (01-08-2006)
    “…To identify molecules that might serve as biomarkers or targets for development of novel molecular therapies, we have been screening genes encoding…”
    Get full text
    Journal Article
  13. 13

    Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis by Hirano, Anna, Yamasaki, Masahiro, Saito, Naomi, Iwato, Koji, Daido, Wakako, Funaishi, Kunihiko, Ishiyama, Sayaka, Deguchi, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki

    Published in Respiratory medicine case reports (01-01-2017)
    “…We present the case of a 79-year-old man who showed multiple pulmonary nodules on chest computed tomography (CT) after being treated for 6 months with…”
    Get full text
    Journal Article
  14. 14

    Smoldering adult T-cell leukemia complicated with pneumocystis pneumonia: A case report by Kawamoto, Kazuma, Yamasaki, Masahiro, Taniwaki, Masaya, Itagaki, Mituhiro, Daido, Wakako, Matsumoto, Yu, Matsumoto, Naoko, Izumi, Yusuke, Otohara, Masaya, Ohashi, Nobuyuki, Hattori, Noboru

    Published in Respiratory medicine case reports (01-01-2021)
    “…Adult T-cell leukemia (ATL) is a tumor of CD4-positive T cells that accompanies an infection by human T-cell lymphotropic virus (HTLV-I). ATL is classified…”
    Get full text
    Journal Article
  15. 15

    First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report by Funaishi, Kunihiko, Yamasaki, Masahiro, Saito, Naomi, Daido, Wakako, Ishiyama, Sayaka, Deguchi, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki

    Published in Case reports in oncology (23-06-2017)
    “…Thymic carcinomas are rare malignant tumors, located in the anterior mediastinum. For the treatment of these carcinomas, several chemotherapy regimens have…”
    Get full text
    Journal Article
  16. 16

    Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer by Yamasaki, Masahiro, Saito, Naomi, Hada, Yu, Miyamoto, Sayaka, Okanobu, Hideharu, Ikeda, Naoya, Daido, Wakako, Ishiyama, Sayaka, Deguchi, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki

    Published in Case reports in oncology (24-04-2017)
    “…Nivolumab is an immune checkpoint inhibitor with demonstrated efficacy against several malignant tumors. Alterations in driver oncogenes such as EGFR and ALK…”
    Get full text
    Journal Article
  17. 17

    Effectiveness of Nivolumab in Large-Cell Neuroendocrine Carcinoma of the Lung - A Report of Two Cases by Daido, Wakako, Yamasaki, Masahiro, Saito, Naomi, Ishiyama, Sayaka, Deguchi, Naoko, Taniwaki, Masaya, Daga, Haruko, Ohashi, Nobuyuki

    Published in Gan to kagaku ryoho (01-01-2017)
    “…The anti-programmed death-1 antibody nivolumab is an important treatment option for non-small-cell lung carcinoma.However, its effectiveness for large-cell…”
    Get more information
    Journal Article
  18. 18
  19. 19
  20. 20